These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. Bickel M, Zangos S, Jacobi V, Lutz T, Knecht G, Goebel F, Staszewski S, Klauke S. HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985 [Abstract] [Full Text] [Related]
3. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy. Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel FD, Crespi CM, Jacobi V, Staszewski S, Klauke S. Scand J Infect Dis; 2008 Sep; 40(1):36-9. PubMed ID: 17852925 [Abstract] [Full Text] [Related]
5. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B. Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744 [Abstract] [Full Text] [Related]
7. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Gillberg P, Bramnert M, Thorén M, Werner S, Johannsson G. Growth Horm IGF Res; 2001 Oct; 11(5):273-81. PubMed ID: 11735245 [Abstract] [Full Text] [Related]
9. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Cancer; 2005 May 15; 103(10):2189-98. PubMed ID: 15822132 [Abstract] [Full Text] [Related]
10. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A. AIDS; 2006 Apr 24; 20(7):1003-10. PubMed ID: 16603852 [Abstract] [Full Text] [Related]
11. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Andersen O, Haugaard SB, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A. Scand J Infect Dis; 2004 Apr 24; 36(11-12):832-9. PubMed ID: 15764170 [Abstract] [Full Text] [Related]
12. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Am J Physiol Endocrinol Metab; 2004 Feb 24; 286(2):E296-303. PubMed ID: 14559725 [Abstract] [Full Text] [Related]
13. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB. Clin Endocrinol (Oxf); 2005 Oct 24; 63(4):428-36. PubMed ID: 16181235 [Abstract] [Full Text] [Related]
14. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Haugaard SB, Andersen O, Vølund A, Hansen BR, Iversen J, Andersen UB, Nielsen JO, Madsbad S. Clin Endocrinol (Oxf); 2005 Mar 24; 62(3):354-61. PubMed ID: 15730419 [Abstract] [Full Text] [Related]
15. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Martínez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, Pérez-Cuevas JB, Casamitjana R, de Lazzari E, Bianchi L, Montserrat E, Roca M, Burgos R, Arnaiz JA, Gatell JM. Antivir Ther; 2003 Oct 24; 8(5):403-10. PubMed ID: 14640387 [Abstract] [Full Text] [Related]
16. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, Eckel RH, Hill JO. Metabolism; 2003 May 24; 52(5):620-5. PubMed ID: 12759894 [Abstract] [Full Text] [Related]
17. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. HIV Med; 2006 Jan 24; 7(1):38-45. PubMed ID: 16313291 [Abstract] [Full Text] [Related]
18. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. JAMA; 2004 Jul 14; 292(2):210-8. PubMed ID: 15249570 [Abstract] [Full Text] [Related]
19. Physical activity is associated with risk factors for chronic disease across adult women's life cycle. Woolf K, Reese CE, Mason MP, Beaird LC, Tudor-Locke C, Vaughan LA. J Am Diet Assoc; 2008 Jun 14; 108(6):948-59. PubMed ID: 18502225 [Abstract] [Full Text] [Related]
20. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. J Infect Dis; 2007 Jun 15; 195(12):1754-61. PubMed ID: 17492590 [Abstract] [Full Text] [Related] Page: [Next] [New Search]